ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026

Kos Biotechnology Partners Announces Inaugural Investment, Leads Epikast’s Financing Round

Author: AI JournalSource: AI Journal
2026/01/31 02:30
  • Alex Tzoukas joins Epikast’s Board of Directors
  • Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos

NEW YORK and ATHENS, Greece, Jan. 30, 2026 /PRNewswire/ — Kos Biotechnology Partners (“Kos”), a global life sciences investment firm, today announced the closing of a financing round in Epikast, a premier provider of technology-enabled commercial and clinical services for the biopharmaceutical industry. This transaction marks the first investment from Kos’ inaugural fund, which is focused on a broad range of investment stages, including the seeding and scaling of high-impact life sciences platforms.

Kos led the round with significant participation from a syndicate of new and existing investors. In conjunction with the financing, Alex Tzoukas, Managing Partner and Co-Founder at Kos, will join Epikast’s Board of Directors.

The capital infusion will enhance Epikast’s proprietary technology platform and the scaling of its specialized service teams. Epikast bridges the gap between high-level medical expertise and cost-efficient operations by leveraging its Greece-based operational hub to serve global biopharmaceutical clients.

Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “Epikast represents an exciting investment for our new fund. The company has developed a differentiated, tech-enabled pharma services model that addresses a clear inefficiency in how biopharma companies engage with healthcare providers and patients. We are pleased to lead this round and support the company as it scales.”

Dr. Stelios Papadopoulos, Chairman of Epikast, added: “We are pleased to welcome Kos Biotechnology Partners as lead investor in this round. Kos brings deep sector expertise and a strong connection to both the US and Greek innovation ecosystems, which aligns well with Epikast’s operating model. Alex’s addition to the board adds valuable perspective as we enter the next phase of growth.”

Dr. Simos Simeonidis, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “We are pleased to partner with Stelios and his team at Epikast with the first investment from our fund. Alex’s deep background as a life sciences investor, investment banker, and operator will further enhance the strong expertise already present on Epikast’s Board.”

Dr. Vangelis Vergetis, CEO of Epikast, concluded: “This financing reinforces Epikast’s strong momentum. We place a premium on partnering with individuals who bring deep expertise and strong judgment. Alex Tzoukas, Simos Simeonidis, and Nikos Kostaras exemplify that and will be valuable partners as we advance our next phase.”

About Epikast

Epikast is a technology-enabled biopharmaceutical services company headquartered in New York with core operations in Athens, Greece. The company provides a comprehensive suite of remote commercial, medical, market access, and patient support services. By combining highly trained medical professionals with a proprietary technology stack, Epikast delivers high-quality engagement and data-driven insights to biopharma clients at a significantly optimized cost structure. It currently partners with several global top 10 pharma companies and smaller biotechnology companies as they commercialize their products in the US and Europe.

About Kos Biotechnology Partners

Kos Biotechnology Partners is a global investment firm founded in 2025 by Dr. Simos Simeonidis and Alex Tzoukas, with a focus on identifying, supporting, and scaling innovative, high-potential opportunities in the life sciences sector. With the launch of its inaugural fund, Kos partners with experienced management teams to build enduring products, services, and platforms through strategic capital, deep operational expertise, and a long-term perspective on value creation.

Media Contacts: info@kosbp.com, info@epikast.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-inaugural-investment-leads-epikasts-financing-round-302675286.html

SOURCE Kos Biotechnology Partners

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Talos Extends Series B to $150M With Strategic Institutional Investors

Talos Extends Series B to $150M With Strategic Institutional Investors

The post Talos Extends Series B to $150M With Strategic Institutional Investors appeared on BitcoinEthereumNews.com. Talos raises an additional $45 million in a
Share
BitcoinEthereumNews2026/01/31 07:49
Headwind Helps Best Wallet Token

Headwind Helps Best Wallet Token

The post Headwind Helps Best Wallet Token appeared on BitcoinEthereumNews.com. Google has announced the launch of a new open-source protocol called Agent Payments Protocol (AP2) in partnership with Coinbase, the Ethereum Foundation, and 60 other organizations. This allows AI agents to make payments on behalf of users using various methods such as real-time bank transfers, credit and debit cards, and, most importantly, stablecoins. Let’s explore in detail what this could mean for the broader cryptocurrency markets, and also highlight a presale crypto (Best Wallet Token) that could explode as a result of this development. Google’s Push for Stablecoins Agent Payments Protocol (AP2) uses digital contracts known as ‘Intent Mandates’ and ‘Verifiable Credentials’ to ensure that AI agents undertake only those payments authorized by the user. Mandates, by the way, are cryptographically signed, tamper-proof digital contracts that act as verifiable proof of a user’s instruction. For example, let’s say you instruct an AI agent to never spend more than $200 in a single transaction. This instruction is written into an Intent Mandate, which serves as a digital contract. Now, whenever the AI agent tries to make a payment, it must present this mandate as proof of authorization, which will then be verified via the AP2 protocol. Alongside this, Google has also launched the A2A x402 extension to accelerate support for the Web3 ecosystem. This production-ready solution enables agent-based crypto payments and will help reshape the growth of cryptocurrency integration within the AP2 protocol. Google’s inclusion of stablecoins in AP2 is a massive vote of confidence in dollar-pegged cryptocurrencies and a huge step toward making them a mainstream payment option. This widens stablecoin usage beyond trading and speculation, positioning them at the center of the consumption economy. The recent enactment of the GENIUS Act in the U.S. gives stablecoins more structure and legal support. Imagine paying for things like data crawls, per-task…
Share
BitcoinEthereumNews2025/09/18 01:27
Tether Achieves Record-Breaking $10 Billion Net Profit as Gold Strategy Redefines Stablecoin Reserves

Tether Achieves Record-Breaking $10 Billion Net Profit as Gold Strategy Redefines Stablecoin Reserves

Tether's extraordinary financial performance in 2025 has fundamentally altered the stablecoin landscape, generating over $10 billion in net profit while amassing
Share
Blockchainmagazine2026/01/31 08:04